Search

Your search keyword '"Aguilera, C."' showing total 8 results
Start Over Author "Aguilera, C." Journal hematological oncology
8 results on '"Aguilera, C."'

2. Orthotopic xenografts models in relapse/refractory lymphomas: a preclinical model for therapeutic, mechanistic and functional studies

Author

Domenech, E. Domingo, primary, Climent, F., additional, Barca, E. Gonzalez, additional, de Lama, E., additional, Lopez‐Pereira, P., additional, Martinez‐Iniesta, M., additional, Calaf, M., additional, Oliveira, A., additional, Montaner, C., additional, Aguilera, C., additional, Banda, E. de la, additional, Villanueva, A., additional, Sureda, A., additional, and Farre, L., additional

Published
2023
Full Text
View/download PDF

3. Effective treatments are required for patients with diffuse large B-cell lymphoma (DLBCL) with primary refractory disease

Author

Salas, Q.Q., primary, Domingo Domenech, E., additional, Mercadal, S., additional, Oliveira, A., additional, Aguilera, C., additional, De la Banda, E., additional, Climent, F., additional, Lucas, A., additional, Garcia, N., additional, Baca, C., additional, Fernandez de Sevilla, A., additional, Sureda, A., additional, and González Barca, E., additional

Published
2017
Full Text
View/download PDF

4. CD30 expression in diffuse large B-cell lymphoma correlates with non-GCB subtype but does not have prognostic impact in patients treated with first line R-CHOP/R-CHOP-like

Author

Salas, Q., primary, Climent, F., additional, Tapia, G., additional, Riasol, M., additional, Mercadal, S., additional, Domingo Domenech, E., additional, Oliveira, A., additional, Moreno-Velázquez, M., additional, Garcia, O., additional, Aguilera, C., additional, Fernandez de Sevilla, A., additional, Sureda, A., additional, Sancho, J., additional, and González Barca, E., additional

Published
2017
Full Text
View/download PDF

5. Short course of R-HyperCVAD/MTX/ARA-C followed by ASCT as first-line therapy in mantle cell lymphoma patients prolongs progression-free survival to more than 9 years

Author

Andrade Campos, M., primary, Mercadal, S., additional, Domingo Domenech, E., additional, Paredes, V., additional, Aguilera, C., additional, Oliveira, A., additional, de la Banda, E., additional, Climent, F., additional, Parody, R., additional, Fernandez de Sevilla, A., additional, Sureda, A., additional, and Gonzalez Barca, E., additional

Published
2017
Full Text
View/download PDF

6. Intralesional rituximab in the treatment of primary cutaneous B‐cell lymphomas: a single‐center experience.

Author

Rampi, N., Muniesa, C., Pereira, P. Lopez, Climent, F., Frias‐Gomez, J., Barca, E. Gonzalez, Oliveira, A. C., Aguilera, C., Sureda, A., Servitje, O., and Domènech, E. Domingo

Subjects
RITUXIMAB, CUTANEOUS T-cell lymphoma, LYMPHOMAS, MUCOSA-associated lymphoid tissue lymphoma
Abstract

B Introduction: b Primary cutaneous B-cell lymphomas (PCBCL) are rare lymphoproliferative disorders characterized by an indolent course and a life-long tendency to relapse. B Methods: b We retrospectively collected data on patients diagnosed with primary cutaneous marginal zone lymphoma (PCMZL) and follicular center lymphoma (PCFCL) who received at least one cycle of ILR from 2010 to 2022 at our Center. All patients experienced at least a partial response (PR), with 58% of complete responses (CR), the majority (80%) reached with only one ILR cycle. [Extracted from the article]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results